Background/Aims: In adenoviral conjunctivitis, the infection process starts by the attachment of adenoviral fibers to conjunctival epithelial cells that contain the receptor for the adenovirus. The α5β1 integrin receptor ligand, GRGDSP peptide, contains the arginine-glycine-aspartate-binding motif which is common to the Coxsackie adenovirus receptor and integrins that are known to be adenoviral receptors. We evaluated the antiadenoviral effect of an expected adenoviral receptor inhibitor, GRGDSP peptide,in vitro. Methods: Adenovirus types 3, 4, 8, 19 and 37 were used. After calculating the 50% cytotoxic concentration of GRGDSP peptide, the adenovirus was cultivated with the agent for 7 days under serial dilution. Adenoviral DNA was qualitatively measured by real-time PCR. Results: GRGDSP peptide showed an inhibitory effect against adenoviral proliferation in all serotypes except type 4 in a dose-dependent manner. Conclusion: This result suggests that the α5β1 integrin receptor ligand, GRGDSP peptide, has antiadenoviral activity in vitro, and the possibility of being used for local treatment of epidemic keratoconjunctivitis.

Keywords:
Adenovirus, α5β1 integrin receptor ligand, GRGDSP peptide, Conjunctivitis
1.
Stehle T, Dermody TS: Structural similarities in the cellular receptors used by adenovirus and reovirus. Viral Immunol 2004;17:129–143.
2.
Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM: Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999;286:1579–1583.
3.
Arnberg N, Edlund K, Kidd AH, Wadell G: Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000;74:42–48.
4.
Huang S, Kamata T, Takada Y, Ruggeri ZM, Nemerow GR: Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996;70:4502–4508.
5.
Nemerow GR, Cheresh DA, Wickham TJ: Adenovirus entry into host cells: a role for alpha(v) integrins. Trends Cell Biol 1994;4:52–55.
6.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309–319.
7.
Davison E, Diaz RM, Hart IR, Santis G, Marshall JF: Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol 1997;71:6204–6207.
8.
Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR: Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol 2001;75:5405–5409.
9.
Meier O, Greber UF: Adenovirus endocytosis. J Gene Med 2003;5:451–462.
10.
Freimuth P: A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol 1996;70:4081–4085.
11.
Lagrota MH, Ciribelli-Guimaraes J, Pereira NA, Wigg MD, Fonseca ME: Antiviral chemotherapy: in vitro activity of ribavirin on DNA and RNA viruses. Rev Latinoam Microbiol 1982;24:121–124.
12.
Lennette DA, Eiferman RA: Inhibition of adenovirus replication in vitro by trifluridine. Arch Ophthalmol 1978;96:1662–1663.
13.
Gordon YJ, Romanowski E, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R, De Clercq E: Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991;16:11–16.
14.
Murphy GF, Wood DP, McRoberts JW, Henslee-Downey PJ: Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol 1993;149:565–566.
15.
Fanourgiakis P, Georgala A, Vekemans M, Triffet A, De Bruyn JM, Duchateau V, Martiat P, De Clercq E, Snoeck R, Wollants E, Rector A, Van Ranst M, Aoun M: Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 2005;40:199–201.
16.
Kaneko H, Kato K, Mori S, Shigeta S: Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res 2001;52:281–288.
17.
Arnberg N, Kidd AH, Edlund K, Olfat F, Wadell G: Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus αv integrins. J Virol 2000;74:7691–7693.
18.
Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995;2:750–756.
19.
Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999;59:219–226.
20.
Tanaka-Yokogui K, Itoh N, Usui N, Takeuchi S, Uchio E, Aoki K, Usui M, Ohno S: New genome type of adenovirus serotype 19 causing nosocomial infections of epidemic keratoconjunctivitis in Japan. J Med Virol 2001;65:530–533.
21.
Wadell G, de Jong JC: Restriction endonucleases in identification of a genome type of adenovirus 19 associated with keratoconjunctivitis. Infect Immun 1980;27:292–296.
22.
Green M, Pina M: Biochemical studies on adenovirus multiplication. 6. Properties of highly purified tumorigenic human adenoviruses and their DNA. Proc Natl Acad Sci USA 1964;51:1251–1259.
23.
Kowalczynska HM, Nowak-Wyrzykowska M, Kolos R, Dobkowski J, Kaminski J: Fibronectin adsorption and arrangement on copolymer surfaces and their significance in cell adhesion. J Biomed Mater Res A 2005;72:228–236.
24.
Oharazawa H, Ibaraki N, Ohara K, Reddy VN: Inhibitory effects of Arg-Gly-Asp (RGD) peptide on cell attachment and migration in a human lens epithelial cell line. Ophthalmic Res 2005;37:191–196.
25.
Durmort C, Stehlin C, Schoehn G, Mitraki A, Drouet E, Cusack S, Burmeister WP: Structure of the fiber head of Ad3, a non-CAR-binding serotype of adenovirus. Virology 2001;285:302–312.
26.
Shayakhmetov DM, Eberly AM, Li ZY, Lieber A: Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 2005;79:1053–1061.
27.
Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N: Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 2004;78:7727–7736.
28.
Mei YF, Lindman K, Wadell G: Human adenoviruses of subgenera B, C, and E with various tropisms differ in both binding to and replication in the epithelial A549 and 293 cells. Virology 2002;295:30–43.
29.
Mei YF, Segerman A, Lindman K, Hornsten P, Wahlin A, Wadell G: Human hematopoietic (CD34+) stem cells possess high-affinity receptors for adenovirus type 11p. Virology 2004;328:198–207.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.